FibroBiologics, Inc. 8-K Report: December 2024 Corporate Update Revealed

Based on the provided section of the financial report, here are the key pieces of information extracted:

1. Entity Identification:

• Company Name: FibroBiologics, Inc.
• CIK (Central Index Key): 0001958777
• SEC File Number: 001-41934
• EIN (Employer Identification Number): 86-3329066

2. Contact Information:

• Address: 455 E. Medical Center Blvd., Suite 300, Houston, TX 77598
• Phone Number: (281) 671-5150

3. Filing Information:

• Form Type: 8-K (a report of unscheduled material events or corporate changes)
• Filing Date: December 27, 2024

4. Stock Information:

• Common Stock Par Value: $0.00001 per share
• Ticker Symbol: FBLG
• Exchange: NASDAQ

5. Financial Context:

• Reporting Period: The report is as of December 27, 2024.
• The unit of measure for financial data is in USD (U.S. Dollars) and shares.

6. Other Metadata:

• Schema Reference: The report references an XBRL schema file (fblg-20241227.xsd) for structured data representation.

Insights:

• The filing indicates a potentially significant corporate event or update as it is reported via an 8-K form, which typically contains important information that shareholders need to know.
• The company is publicly traded on NASDAQ, indicating it is subject to regular financial disclosures and compliance requirements.
• The par value of the common stock is very low ($0.00001), which may suggest that the company is in an early growth stage or has undergone stock restructuring.

This extracted information would be valuable for investors, analysts, or stakeholders interested in FibroBiologics, Inc.'s financial health and corporate activities.